Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 320 participants.

Also called NCT06435156

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 320 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06435156
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06435156. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-28 (actual); primary completion 2027-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
Acronym
SOPHIST
Condition
Type 1 Diabetes
Condition
Heart Failure
Intervention (Drug)
Sotagliflozin
Intervention (Drug)
Placebo
Lead sponsor
University of Dundee (class: other)
Collaborator
Lexicon Pharmaceuticals (class: industry)
Collaborator
Juvenile Diabetes Research Foundation (class: other)

Record details

Record id
cardio:ct-nct06435156
Content hash
62467e6b262877900217a4e3a8c0f932e5741ce6df1be59fc152af8a67806b34